David Zaccardelli - Dova Pharmaceuticals President CEO
CEO
Dr. David Zaccardelli Pharm.D. is President, Chief Executive Officer of the company. Dr. Zaccardelli has served as our President and Chief Executive Officer since December 2018. Prior to joining us, Dr. Zaccardelli served as the acting Chief Executive Officer of Cempra Pharmaceuticals, Inc. from December 2016 until the company merger with Melinta Therapeutics, Inc in November 2017. From 2004 until 2016, Dr. Zaccardelli served in several senior management roles at United Therapeutics Corporationrationration, including chief operating officer, chief manufacturing officer and executive vice president, pharmaceutical development and operations. Prior to joining United Therapeutics, Dr. Zaccardelli founded and led a startup company focused on contract pharmaceutical development services, from 1997 through 2003. From 1988 to 1996, Dr. Zaccardelli worked at Burroughs Wellcome Co. and Glaxo Wellcome, Inc. in a variety of clinical research positions. He also served as director of clinical and scientific affairs for Bausch Lomb Pharmaceuticals from 1996 to 1997. Dr. Zaccardelli currently serves on the Board of Directors of Melinta Therapeutics, Inc. as well as several private healthcare companies since 2018.
| Age | 54 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 919 748-5975 |
| Web | www.dova.com |
David Zaccardelli Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Zaccardelli against Dova Pharmaceuticals stock is an integral part of due diligence when investing in Dova Pharmaceuticals. David Zaccardelli insider activity provides valuable insight into whether Dova Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Dova Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Dova Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Zaccardelli over six months ago Exercise or conversion by David Zaccardelli of 4000 shares of United Therapeutics subject to Rule 16b-3 |
Dova Pharmaceuticals Management Efficiency
Dova Pharmaceuticals' management efficiency ratios could be used to measure how well Dova Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 22.25 M in liabilities with Debt to Equity (D/E) ratio of 43.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Dova Pharmaceuticals has a current ratio of 5.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Dova Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Dova Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dova Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dova to invest in growth at high rates of return. When we think about Dova Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 13 records | CEO Age | ||
| Todd Penegor | The Wendys Co | 59 | |
| Frederic Landtmeters | Molson Coors Brewing | 50 | |
| Charles Morrison | Wingstop | 49 | |
| Mark Hunter | Molson Coors Brewing | 55 | |
| Edward Bernstein | Westrock Coffee | 63 | |
| Sergey Yeskov | Molson Coors Brewing | 47 | |
| Simon Cox | Molson Coors Brewing | 52 | |
| Emil Brolick | The Wendys Co | 68 | |
| Kirk Tanner | The Wendys Co | 55 | |
| Gavin Hattersley | Molson Coors Brewing | 61 | |
| Stewart Glendinning | Molson Coors Brewing | 51 | |
| Michael Skipworth | Wingstop | 46 | |
| Krishnan Anand | Molson Coors Brewing | 60 | |
Management Performance
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -1.0E-4 |
Dova Pharmaceuticals Leadership Team
Elected by the shareholders, the Dova Pharmaceuticals' board of directors comprises two types of representatives: Dova Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dova. The board's role is to monitor Dova Pharmaceuticals' management team and ensure that shareholders' interests are well served. Dova Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dova Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Goldman, Independent Director | ||
| Douglas Blankenship, CFO | ||
| Alfred Novak, Independent Director | ||
| Alex Sapir, President CEO, Director | ||
| Lee Allen, Chief Medical Officer | ||
| Sean Stalfort, Director | ||
| Kevin Laliberte, Senior Vice President - Product Development | ||
| Roger Jeffs, Independent Director | ||
| David Zaccardelli, President CEO | ||
| Nancy Wysenski, Independent Director | ||
| Mark Hahn, CFO, Principal Financial Officer and Principal Accounting Officer | ||
| Paul Manning, Chairman of the Board | ||
| Jason Hoitt, Chief Commercial Officer |
Dova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dova Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -1.0E-4 | |||
| Profit Margin | (0.06) % | |||
| Operating Margin | (541.38) % | |||
| Current Valuation | 380.37 M | |||
| Shares Outstanding | 28.8 M | |||
| Shares Owned By Insiders | 62.25 % | |||
| Shares Owned By Institutions | 40.63 % | |||
| Number Of Shares Shorted | 1.19 M | |||
| Price To Earning | (12.63) X |
Pair Trading with Dova Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dova Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dova Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Jabil Circuit could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jabil Circuit when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jabil Circuit - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jabil Circuit to buy it.
The correlation of Jabil Circuit is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jabil Circuit moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jabil Circuit moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jabil Circuit can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Dova Stock
If you are still planning to invest in Dova Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dova Pharmaceuticals' history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |